Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for ...
CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital ...
Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner, allows Crossject to benefit from strong ...
Dijon, France 27 May 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE®, an emergency ...
Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without ...
Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized loans France 2030 Plan dedicated to supporting French ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results